However, as these two trials included few patients with non‐classic EGFR mutations (26.0% and 6.3%, respectively) and reported a relatively high proportion of patients experiencing grade 3 or 4 treatment‐related adverse events (TRAEs) with the four‐drug regimen, it is necessary to identify regimens with better tolerability and comparable efficacy for patients with NSCLC harboring rare EGFR mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.